Testosterone Level and Coronary Artery Disease in Iranian Men; a Systematic Review
Men's Health Journal,
Vol. 5 No. 1 (2021),
6 January 2021
,
Page e22
https://doi.org/10.22037/mhj.v5i1.34985
Abstract
Coronary artery disease (CAD) is among the most common cardiovascular diseases (CVDs), caused by the formation of plaques of lipids, calcium, and inflammatory cells. In Iran, CAD is responsible for about 50% of all deaths per year. There is also a probability of the role of androgens deficiency in CAD in men. We aimed to systematically review all the related original studies to achieve an overall insight into the associations of testosterone and CAD in Iranian men.
MedLine, Web of Science, Scopus, and Google scholar databases were searched from inception to January 2021. All types of studies on Iranian men older than 40 years of age, reporting results of comparing testosterone in normal individuals and those with CAD were included. The main findings of the articles were compared to achieve an overall statement.
Ultimately, six studies were included. Most (66.7%) had directly stated that lower levels of testosterone are associated with CAD or the level of testosterone is lower in patients with proven CAD. Among them, in 3 (50%) studies, the mean age of the participants had no significant difference between patients with CAD and the normal group.
It is clear that low testosterone level is associated with increased risk of cardiovascular events but it is not definitely determined whether it is independent of age in Iranian men. Further well-designed studies are needed to clearly exclude all confounding variables including age and show the net effect of testosterone on CAD.
- Coronary artery disease
- Testosterone
- Atherosclerosis
- Men
How to Cite
References
2. Heart Disease Facts: https://www.cdc.gov/heartdisease/facts.htm; 2020 [updated 2020,Sep 08.
3. Musunuru K, Kathiresan S. Genetics of common, complex coronary artery disease. Cell. 2019;177(1):132-45.
4. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. Journal of cellular physiology. 2019;234(10):16812-23.
5. Poorzand H, Tsarouhas K, Hozhabrossadati SA, Khorrampazhouh N, Bondarsahebi Y, Bacopoulou F, et al. Risk factors of premature coronary artery disease in Iran: A systematic review and meta‐analysis. European journal of clinical investigation. 2019;49(7):e13124.
6. Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart views: the official journal of the Gulf Heart Association. 2017;18(3):109.
7. Shao C, Wang J, Tian J. Coronary Artery Disease: From Mechanism to Clinical Practice. Coronary Artery Disease: Therapeutics and Drug Discovery: Springer; 2020. p. 1-36.
8. Chistiakov DA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Role of androgens in cardiovascular pathology. Vascular health and risk management. 2018;14:283.
9. Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. Journal of the American Heart Association. 2013;2(6):e000272.
10. Bianchi VE. Testosterone, myocardial function, and mortality. Heart failure reviews. 2018;23(5):773-88.
11. Alkamel A, Shafiee A, Jalali A, Boroumand M, Nozari Y. The association between premature coronary artery disease and level of testosterone in young adult males. Archives of Iranian medicine. 2014;17(8):0-.
12. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology. 2011;165(5):687.
13. Allameh F, Pourmand G, Bozorgi A, Nekuie S, Namdari F. The association between androgenic hormone levels and the risk of developing coronary artery disease (CAD). Iranian journal of public health. 2016;45(1):14.
14. Zeller T, Appelbaum S, Kuulasmaa K, Palosaari T, Blankenberg S, Jousilahti P, et al. Predictive value of low testosterone concentrations regarding coronary heart disease and mortality in men and women–evidence from the FINRISK 97 study. Journal of internal medicine. 2019;286(3):317-25.
15. Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC medical research methodology. 2014;14(1):1-5.
16. Fallah N, Mohammad K, Nourijelyani K, Eshraghian MR, Seyyedsalehi SA, Raiessi M, et al. Nonlinear association between serum testosterone levels and coronary artery disease in Iranian men. European journal of epidemiology. 2009;24(6):297-306.
17. Separham A, Ghaffari S, Sohrabi B, Aslanabadi N, Bavil MH, Lotfollahi H. Association of admission testosterone level with ST-segment resolution in male patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Basic and clinical andrology. 2017;27(1):1-9.
18. Davoodi G, Amirzadegan A, Boroumand MA, Dehkordi MR, Saeid AK, Sharif AY, et al. Association between androgenic hormone levels and left ventricular ejection fraction. The Journal of Tehran Heart Center. 2010;5(3):141.
19. Davoodi G, Amirezadegan A, Borumand MA, Dehkordi MR, Kazemisaeid A, Yaminisharif A. The relationship between level of androgenic hormones and coronary artery disease in men. Cardiovascular journal of Africa. 2007;18(6):362.
20. Ariabod V, Qara M, Payan K, Hosseini SN. COMPARISON OF TESTOSTERONE LEVEL IN PATIENTS WITH MYOCARDIAL INFARCTION WITH CONTROL GROUP. Pakistan Heart Journal. 2019;52(2).
21. Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian journal of andrology. 2012;14(3):428.
22. Elagizi A, Köhler TS, Lavie CJ, editors. Testosterone and cardiovascular health. Mayo Clinic Proceedings; 2018: Elsevier.
23. Davis SR, Wahlin-Jacobsen S. Testosterone in women—the clinical significance. The lancet Diabetes & endocrinology. 2015;3(12):980-92.
24. Lai J, Ge Y, Shao Y, Xuan T, Xia S, Li M. Low serum testosterone level was associated with extensive coronary artery calcification in elderly male patients with stable coronary artery disease. Coronary artery disease. 2015;26(5):437-41.
25. Park B-J, Shim J-Y, Lee Y-J, Lee J-H, Lee H-R. Inverse relationship between bioavailable testosterone and subclinical coronary artery calcification in non-obese Korean men. Asian journal of andrology. 2012;14(4):612.
26. Gururani K, Jose J, George PV. Testosterone as a marker of coronary artery disease severity in middle aged males. Indian heart journal. 2016;68:S16-S20.
27. Turhan S, Tulunay C, Güleç S, Özdöl Ç, Kilickap M, Altn T, et al. The association between androgen levels and premature coronary artery disease in men. Coronary artery disease. 2007;18(3):159-62.
28. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. The Journal of Clinical Endocrinology & Metabolism. 2002;87(8):3632-9.
29. Hu X, Rui L, Zhu T, Xia H, Yang X, Wang X, et al. Low testosterone level in middle-aged male patients with coronary artery disease. European journal of internal medicine. 2011;22(6):e133-e6.
30. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96(22):1821-5.
31. Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. Jama. 2017;317(7):708-16.
32. Carson III CC, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. The journal of sexual medicine. 2012;9(1):54-67.
33. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60(11):1451-7.
34. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al., editors. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings; 2007: Elsevier.
35. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2010;95(6):2560-75.
- Abstract Viewed: 328 times
- pdf Downloaded: 144 times